Pharmacokinetics of recombinant human interleukin-3 in rhesus monkeys

Concentration-time profiles of ~(125)I-labeled recombinant human interleukin-3 (125IrhIL-3) were de-termined by reverse phase high performance liquid chromatography (RHPLC) after intravenous and subcutaneous ad-ministration of the drug in 16 rhesus monkeys. The initial and terminal T1/2 in plasma after intravenous of 30 μg/kg were (0. 15 ±0.13) and (2. 21 ± 0. 59) h, respectively. Terminal half-lives after 30, 90 and 180μg/kg subcutaneous (s.c.) injections were 2. 0-3.8 h. Area under concentration-time curves (AUC) following s. c. were roughly in-creased with dose, while CL5 were similar among different dosages. The absorption rates were dependent on concentra-tion at injected site. Bioavailability was about 0.7 after s.c. Rapid biodegradation was found in plasma. Distribution profiles of total radioactivity were as follows: the highest level was found in urinary system; levels in bile-enteric sys-tem, lymph nodes, bone marrow and spleen were near to that in plasma, and level in brain was the lowest     

基因重组人白细胞介素-3在猴中的药代动力学

猕猴静脉注射¹²⁵Ⅰ标记基因重组人白细胞介素-3(30μg/kg)后RHPLC测定血浆浓度曲线,快速和末端半衰期分别为(0.15± 0.13)和(2.21± 0.59)h.皮下注射30,90和180μg/kg消除半衰期2.0～3.8 h,AUC基本上随皮下注射(SC)剂量而增大,CL_s相近 吸收受注射部位浓度限制.生物利用度0.71.药物在体内迅速降解.组织分布泌尿系统浓度最高,胆肠道、淋巴、骨髓和脾等与血浆相近,脑最低尿分析提示肾是降解器官之一